Quest Diagnostics Incorporated (NYSE:DGX) Shares Sold by Stifel Financial Corp

Stifel Financial Corp cut its stake in Quest Diagnostics Incorporated (NYSE:DGXFree Report) by 3.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,049 shares of the medical research company’s stock after selling 2,336 shares during the period. Stifel Financial Corp owned approximately 0.06% of Quest Diagnostics worth $9,659,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in DGX. TD Asset Management Inc increased its position in shares of Quest Diagnostics by 6.5% during the 4th quarter. TD Asset Management Inc now owns 40,099 shares of the medical research company’s stock valued at $5,529,000 after purchasing an additional 2,431 shares during the period. Pine Valley Investments Ltd Liability Co raised its position in Quest Diagnostics by 27.4% in the fourth quarter. Pine Valley Investments Ltd Liability Co now owns 21,528 shares of the medical research company’s stock worth $2,968,000 after acquiring an additional 4,627 shares in the last quarter. Hilltop Holdings Inc. acquired a new stake in Quest Diagnostics in the 4th quarter valued at about $224,000. Wilson & Boucher Capital Management LLC bought a new position in shares of Quest Diagnostics during the 4th quarter valued at about $207,000. Finally, Intech Investment Management LLC grew its stake in shares of Quest Diagnostics by 14.7% in the 4th quarter. Intech Investment Management LLC now owns 88,330 shares of the medical research company’s stock worth $12,179,000 after purchasing an additional 11,306 shares during the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on DGX shares. Barclays increased their target price on shares of Quest Diagnostics from $138.00 to $144.00 and gave the company an “equal weight” rating in a research note on Thursday, April 25th. Jefferies Financial Group upgraded Quest Diagnostics from a “hold” rating to a “buy” rating and lifted their target price for the stock from $140.00 to $155.00 in a report on Wednesday, February 7th. SVB Leerink started coverage on Quest Diagnostics in a report on Monday, February 26th. They set a “market perform” rating and a $135.00 target price for the company. UBS Group increased their price target on Quest Diagnostics from $139.00 to $146.00 and gave the company a “neutral” rating in a research report on Wednesday, April 24th. Finally, StockNews.com upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Friday, May 24th. Nine investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $146.67.

Get Our Latest Report on Quest Diagnostics

Insider Buying and Selling

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 1,760 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $140.00, for a total value of $246,400.00. Following the completion of the sale, the senior vice president now directly owns 13,435 shares of the company’s stock, valued at $1,880,900. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.79% of the stock is currently owned by corporate insiders.

Quest Diagnostics Stock Up 0.8 %

Quest Diagnostics stock opened at $142.69 on Thursday. Quest Diagnostics Incorporated has a twelve month low of $119.59 and a twelve month high of $145.62. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.89 and a current ratio of 0.97. The firm has a market cap of $15.85 billion, a PE ratio of 19.20, a P/E/G ratio of 3.06 and a beta of 0.90. The firm’s 50 day moving average price is $136.20 and its two-hundred day moving average price is $133.42.

Quest Diagnostics (NYSE:DGXGet Free Report) last posted its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.18. The business had revenue of $2.37 billion for the quarter, compared to the consensus estimate of $2.29 billion. Quest Diagnostics had a net margin of 9.11% and a return on equity of 15.52%. Quest Diagnostics’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.04 earnings per share. On average, research analysts predict that Quest Diagnostics Incorporated will post 8.79 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 22nd. Investors of record on Monday, July 8th will be issued a $0.75 dividend. The ex-dividend date is Monday, July 8th. This represents a $3.00 dividend on an annualized basis and a yield of 2.10%. Quest Diagnostics’s dividend payout ratio is currently 38.22%.

About Quest Diagnostics

(Free Report)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

See Also

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGXFree Report).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.